Taro Pharmaceutical Industries (NYSE:TARO) PT Lowered to $105.00

Taro Pharmaceutical Industries (NYSE:TARO) had its target price reduced by HC Wainwright from $115.00 to $105.00 in a research note published on Monday, The Fly reports. HC Wainwright currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Taro Pharmaceutical Industries from a hold rating to a strong sell rating in a research report on Thursday, June 13th. TheStreet cut Taro Pharmaceutical Industries from a b- rating to a c rating in a report on Thursday, May 23rd. Finally, ValuEngine cut Taro Pharmaceutical Industries from a hold rating to a sell rating in a report on Thursday, May 23rd.

Taro Pharmaceutical Industries stock opened at $80.52 on Monday. The stock has a market cap of $3.21 billion, a PE ratio of 11.14 and a beta of 0.48. The stock has a 50-day moving average price of $83.07 and a 200 day moving average price of $96.42. Taro Pharmaceutical Industries has a 52 week low of $76.93 and a 52 week high of $110.30.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings data on Thursday, August 8th. The company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.24). The company had revenue of $161.30 million for the quarter, compared to analysts’ expectations of $169.80 million. Taro Pharmaceutical Industries had a return on equity of 13.79% and a net margin of 41.49%. Equities research analysts predict that Taro Pharmaceutical Industries will post 8.98 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter worth about $20,825,000. Renaissance Technologies LLC grew its holdings in shares of Taro Pharmaceutical Industries by 29.6% during the 2nd quarter. Renaissance Technologies LLC now owns 552,964 shares of the company’s stock worth $47,234,000 after purchasing an additional 126,164 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Taro Pharmaceutical Industries by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 360,414 shares of the company’s stock worth $38,954,000 after purchasing an additional 51,826 shares during the period. AJO LP grew its holdings in shares of Taro Pharmaceutical Industries by 23.6% during the 1st quarter. AJO LP now owns 216,550 shares of the company’s stock worth $23,407,000 after purchasing an additional 41,416 shares during the period. Finally, First Manhattan Co. purchased a new stake in shares of Taro Pharmaceutical Industries during the 1st quarter worth about $3,810,000. Institutional investors own 9.79% of the company’s stock.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Further Reading: How does inflation affect different investments?

The Fly

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.